Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLASTM Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company’s study evaluating its next-generation vCLASTM Ultra Ultra-Low Temperature Ablation (“ULTA”) Ventricular Ablation System. The study is designed to support a Premarket Approval (“PMA”) supplement to the Company’s PMA f